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Abstract. Thioridazine (TZ), an antipsychotic drug, renders 
multidrug-resistant (MDR) cancer cells susceptible to 
cytotoxic agents to which they were initially resistant, has 
anti-prolilferative activity and apoptosisQnducing properties 
in various tumor cell lines and cancer stem cells. Whereas 
the anti-proliferative activity takes place at high 
concentrations that ensure the intercalation of the compound 
between nucleic bases (especially rich in G/C bases), much 
lower concentrations inhibit the export function o f the 
ABCB1 (P-glycoprotein), which is responsible for the MDR 
phenotype of the cancer cell. The co-administration o f TZ 
with doxorubicin inhibits efflux o f doxorubicin and, hence, 
increases the intracellular concentration of anticancer drug. 
The (+) and (-) enantiomers o fTZ have the same activities 
as TZ. The main focus of this review is to present extensive 
evidence provided by our work, confirmed by much later 
studies, as it supports adjuvant use of TZ with an anticancer 
drug for MDR cancer therapy.
Phenothiazines are heterocyclic compounds that have 
specific and non-specific activities against constituents of the 
plasma membrane of eukaryotes. Although the first 
phenothiazines were synthesized in the late 19th century, the 
basic phenothiazine structure is identical to that of the well-
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known dye methylene blue, which was first prepared as a 
stain in 1876 by the German chemist Heinrich Caro as a 
derivative from an existing phenothiazine (1). Paul Ehrlich 
studied methylene blue (Figure 1) for biological properties 
and found that it could reduce the mobility of bacteria (1). 
The demonstration by Bodoni at the end of the 19th century 
that methylene blue could render a human lethargic, spurred 
investigations of the possible use of this dye to control 
psychosis (2). It took more than 50 years to produce a 
colorless methylene blue-type compound by the French 
chemist Charpentier of Rhone-Poulenc called 
chlorpromazine (CPZ) that had the desired neuroleptic 
properties for therapy psychosis (3). However, because of its 
toxic side-effects, the compound was soon replaced with the 
equally effective phenothiazine neuroleptic thioridazine (TZ) 
whose most frequent side-effect was somnolence (Figure 1). 
The early wide use of CPZ indicated that, apart from their 
basic neuroleptic action related to the blockade of 
dopaminergic receptors, CPZ affected diverse biological 
activities, such as the calcium transporter calmodulin, protein 
kinase C, as well as many other enzymes that, when 
inhibited by CPZ, promoted anti-proliferative effects (4, 5). 
The enhancement of antibiotic activity by CPZ on bacteria 
and the demonstration that multidrug-resistant (MDR) 
Mycobacterium tuberculosis could b^ ^nhibited in its 
replication by CPZ and TZ (6) that*"file reversal of
antibiotic resistance was the result of inhibition of the efflux 
pump system of mycobacteria (6) and bacteria (7). In 
addition, similar inhibitory effects of the ABCB1 transport 
function were demonstrated using MDR mouse T-lymphoma 
cells (8). The relevant possibilities to MDR cancer were 
supported by the antihelmintic and antibacterial activities of 
phenothiazines described in the 1930s and 1940s (5). 
Phenothiazines have been in use for the treatment of 
psychiatric disorders since the 1950s. In addition, various 
other effects of phenothiazines have since been described,
i
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Methylene blue
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Figure 1. Chemical structure of some important phenothiazines.
such as anti-mycobacterial (9), anti-plasmid (10) and 
immunomodulatory (11) activities. The substituents in the 
phenothiazine ring, which increase lipophilicity, amplify 
their anti-proliferative activity in cancer cells (12). The 
presence of different substituents into the phenothiazine 
skeleton, as well as the modification of the tricyclic ring 
system, alters their biological effect (13). Because of their 
highlighted biological activity, numerous derivatives of 
phenothiazines have been synthesized and patented (5).
Thioridazine, (10-[2-(l-methyl-2-piperidinyl)ethyl]-2- 
(methylthio)-lOH-phenothiazine), was previously used 
extensively as an antipsychotic drug; however, there is an 
increasing number of studies demonstrating its anticancer, 
multidrug resistance-reversing and apoptosis-inducing 
properties in various tumor cell lines. This review intends to 
give an overview of the MDR-reversing activity of 
thioridazine that has resulted from our decades of published 
research studies, many of which have been recently 
confirmed by others, although correct citation of their 
existence has been omitted willfully or otherwise.
Membrane Destabilizing Effects
Phenothiazines demonstrate a strong affinity to lipid bilayers 
of cell membranes because of the high degree of lipophilicity 
of the phenothiazine ring (12). Thioridazine (TZ) interacts with
Chlorpromazine
Thioridazine ()-enantiomer
the inner mitochondrial membrane. Consequently, TZ presents 
with antioxidant and peroxidation activities on membrane 
lipids of the mitochondria, with these effects resulting in 
transient alterations of mitochondrial permeability, thus 
promoting release of cytochrome c from mitochondria (14).
Effect on Cell Cycle
According to in silico gene signature based studies, TZ inhibits 
the phosphatidylinositol-3’-kinase (PI3K)/Akt pathway and, 
thus, exerts cytotoxicity in ovarian cancer cells (15).
Translationally controlled tumor protein (TCTP) is an 
essential regulator of apoptosis and cell cycle events (16). In 
508 breast cancers, high-TCTP status is associated with 
aggressive G3-grade tumors, predicting poor prognosis. TZ 
increases P53 expression by counteracting the ubiquitination 
of P53 that is enhanced by TCTP (17).
Anti-calmodulin Activity
Calmodulin is a calcium binding protein that regulates 
calcium-dependent biochemical processes and, hence is 
involved in a large variety of cellular functions. Since TZ is 
a potent inhibitor of calmodulin, calcium binding and many 
calcium-dependent enzymes that are involved in cellular 
proliferation become destabilized. Thus, when calmodulin is
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inhibited from binding calcium by TZ, these enzymes deny 
access to calcium, and, hence, their reduced activity results 
in the inhibition of cell proliferation (12). Similarly, many 
biochemical pathways, dependent upon access to calcium, 
are similarly inhibited (12, 18).
Effect on DNA Damage
TZ can interfere with DNA damage responses and DNA 
repair. Furthermore, TZ is an inhibitor of Tousled-like 
kinases (TLKs), enzymes responsible for the maintenance of 
genomic stability (19). As described previously, TZ has anti­
plasmid activity by eliminating the drug resistance-carrying 
plasmids of bacteria (20).
TZ as Dopamine Receptor Antagonist
TZ is an antagonist of the dopamine D2 receptor (DRD2) 
and, according to previous reports, DRD2 could be a 
promising therapeutic target in cervical cancer therapy. It has 
been shown that TZ inhibits cellular proliferation through 
down-regulation of DRD2 expression. Moreover, TZ can 
inhibit proliferation of human uterine cervical carcinoma 
cells and induce apoptosis and necrosis (21). TZ can inhibit 
the PI3K/Akt/mTOR/p70S6K signaling pathway and has 
cytotoxic activity on cervical and endometrial cancer cells 
by inducing cell cycle arrest and apoptosis (22).
Activity on Stem Cells
TZ is a selective inducer of the differentiation of cancer stem 
cells (CSC) and the anti-CSC activity of TZ is due to its 
antagonistic effect on DRD2 receptors that are differentially 
expressed on neoplastic stem cells. It is important to note 
that TZ has no effect on normal human somatic stem cells 
implying that TZ could be a selective anti-CSC drug (23).
TZ exerts an apoptotic effect in brain-derived tumors; 
furthermore, the sensitivity of neoplasm tissue to thioridazine 
is higher than that on primary (normal) brain cells (24). With 
I the use fcioinformatic tools, it has been demonstrated that TZ 
is a potent anti-glioblastoma and anti-glioblastoma cancer 
stem-like cell agent. Moreover, because autophagy might be 
a major mechanism of the anti-glioblastoma activity and TZ 
has proved to be an effective glioblastoma tumor growth 
inhibitor that can induce autophagy in vivo, the rediscovery 
of TZ as an anticancer agent could be used as a powerful 
| strategy therapy, against malignant tumors with a poor 
prognosis (25).
Apoptosis Induction
TZ induces apoptosis in leukemic cells without any influence 
on the viability of normal lymphocytes (26). It also induces
apoptosis of B16 melanoma cells and demonstrates in vivo 
anti-tumor activity (27). The in vivo activity of TZ was 
studied using female C57/B1 mice. Animals were inoculated 
with wild-type B16 melanoma cells by intravenous (i.v.) 
injection into the tail vein. Mice were treated with TZ (10 and 
15 mg/kg x 3/weeks intraperitoneally (i.p.) or 15 and 25 
mg/kg/day per os (p.o.)) and, after autopsy, the lung weight 
and number of pulmonary melanoma colonies were 
determined. TZ administration (i.p. or p.o.) resulted in the 
reduction of lung tumor burden and an increase in mice 
survival (27).
It was demonstrated that TZ induces apoptosis of the 
MDR mouse T-lymphoma cells at 5 and 10 pg/ml 
concentrations (8). During apoptosis, the plasma membrane 
undergoes multiple changes: the translocation of 
phosphatidylserine from the inner to the outer leaflet of the 
plasma membrane can be detected by annexin V. After 
treatment with 10 pg/ml of TZ, 49.54% of the cells were 
early-apoptotic and 27.26% showed late-apoptotic and 
necrotic features, although the proportion of dead cells was 
3.4% in MDR mouse T-lymphoma cells (8). The apoptosis- 
inducing effect of TZ was confirmed by other studies using 
various cell lines (28).
Efflux Pump Inhibition
The major mechanism for the MDR phenotype is the 
overexpression of ATP-dependent transporters known as the 
ATP-binding cassette (ABC) family. In humans, the three 
major types of MDR proteins include members of the ABCB 
(ABCB 1/MDRl/P-glycoprotein), the ABCC (ABCC1/MRP1, 
ABCC2/MRP2, probably also ABCC3-6 and ABCC10-11) 
and the ABCG (ABCG2/MXR/BCRP) sub-family (29). The 
relationship between ABC expression levels and sensitivity 
to drugs or possible drug candidates is of great importance 
concerning anticancer chemotherapy.
Substances, such as verapamil and TZ, which can block 
ABCB1 or P-glycoprotein, can reverse resistance of 
doxorubicin-resistant sarcoma 180 (SI80) cells completely 
(30). According to Spengler,et al.  ^TZ induces apoptosis of 
the MDR lymphoma cells and inhibits the activity of their 
overexpressed ABCB1 transporter. However, the 
concentrations that produce these in vitro results are 
extremely high and greater than that clinically employed for 
the therapy of severe psychosis (8).
Anti-angiogenesis
Angiogenesis is essential for tumor growth and metastasis 
and targeting angiogenesis could be a promising objective 
for anticancer drug development. Expression of vascular 
endothelial growth factor (VEGF) and hypoxia-inducible 
factor la  (HIF-la), as well as the phosphorylation of
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VEGFR-2 were reduced in a thioridazine-treated tumor (31). 
TZ is an angiostatic agent found to effectively inhibit 
angiogenesis in a murine tumor model reducing microvessel 
density in vivo (32).
Stereochemistry and Pharmacological Activity
The consideration of stereochemistry in drug action is gaining 
ever-greater attention in medical practice. Many of the drugs 
currently used in psychiatric practice are mixtures of 
enantiomers. For some therapeutics, single-enantiomer 
formulations can provide greater selectivity for their biological 
targets and/or better pharmacokinetics compared to the 
mixture of enantiomers. When both a single enantiomer and a 
racemic formulation of a drug are available, the information 
from experimental evidences should be used to decide which 
formulation is most appropriate (33). The potential advantages 
of using single enantiomers of a chiral drug were investigated 
by Csonka et al. (34). The equilibrium between the (+) and (- 
) isomers influences the binding affinities of the enantiomers 
to different ligands or receptors. “Do the racemate TZ and its 
enantiomers express different activities against cancer cell 
lines?” This question was based upon observations published 
by others who suggested that “the (-)-TZ enantiomer had 
slightly more catalepsy (neuroleptic)” (35). Nevertheless, a 
variety of pharmacological studies, as reported by Svendsen 
et al. (35), indicate significantly greater binding of the (-)-TZ 
enantiomer to the D1 receptor of the rodent brain. Regardless, 
our results clearly demonstrate that the racemate TZ and its 
enantiomers have essentially the same activity against cancer 
cell lines with respect to the inhibition of replication, induction 
of apoptosis and inhibition of ABCB1 (34). The central 
nervous system (CNS) receptor stereospecificity of (+) and (- 
)-TZ was first described by Svendsen et al. in 1988 (35). 
Optical isomers, such as those of TZ, exhibit significant 
differences in their affinities for receptor sites, 
biotransformation and binding to serum and tissue proteins. 
Separation of the racemate TZ into its enantiomers in the 
human body has been measured (36). In these investigations, 
the (-) enantiomer was found to be at higher concentrations 
than the (+) enantiomer in the different tissues. The general 
possibility for using the resolution of commercially available 
racemates in therapeutics for an anxiolytic effect has been 
described by Baumann et al. (36) based on the investigations 
and statements made by Ariens et al. (37). The role of the 
chirality of other compounds known to affect ABCB1, such as 
the enantiomers of verapamil, has been investigated. These 
latter studies indicated that the L and the D forms of verapamil 
had equal abilities to reverse the in vitro resistance of MDR 
leukemic cells to drugs, such as vincristine (38). The 
mechanism of action of TZ has been analyzed in detail by 
Spengler et al. who showed that the racemate is able to induce 
the apoptosis of MDR mouse T-lymphoma cells (8). In this
latter study, the differential effects of the two TZ enantiomers 
were not examined. As previously stated, the anti-proliferative 
effects of the racemate and (+) and (-) enantiomers of TZ on 
MDR mouse T-lymphoma cells overexpressing ABCB 1 were 
investigated by Csonka et al. (34) and no significant 
differences were found between the three compounds.
In order to avoid the toxic side-effect of resistance- 
reversing compounds, drugs with selective inhibition of the 
MDR in cancer cells are needed. To achieve this effect, three 
classes of known neuroleptic drugs (methotrimeprazine, 
clopenthixol and butaclamol isomers) with active and inactive 
stereoisomers were tested for MDR efflux pump inhibition on 
mouse T-lymphoma cell lines (39). Their anti-proliferative 
effects on sensitive and MDR cancer cell cultures were 
compared with those of the classical resistance modifier 
verapamil. It was confirmed that enantiomers of 
phenylalkylamines proved to be equally potent inhibitors of 
drug transport by ABCB1 (39). However, CNS-active andf" I 
inactive butaclamol enantiomers exerted slightly different 
effects on the reversal of the MDR phenotype, which means 
that drug binding might have weak enantioselectivity for 
ABCB1 (39), suggesting that some enantiomers of compounds 
that inhibit ABCB 1 can be exploited as adjuvants to cytostatic 
chemotherapy of cancer in order to increase the efficacy of the 
cancer agent. However, the separate use of one enantiomer of 
TZ versus the other did not appear to provide any advantage 
over racemic TZ for the adjuvant therapy of MDR cancer.
The combination therapy using a conventional 
chemotherapeutic drug with an agent that can improve the 
action of the anticancer drug without any additional side- 
effects could be a good approach to treat MDR cancer. TZ 
showed a moderate synergism to doxorubicin in P388/ADR 
murine leukemia cells described by Ramu et al. (40).
It has been confirmed that calmodulin inhibitors 
significantly enhanced the cytotoxic effects of doxorubicin 
in the resistant but not parent-sensitive P388 cells (41). To 
administer TZ and doxorubicin to in vitro and in vivo 
systems, polymeric micelles have been designed as delivery 
carriers (42). The combination therapy with TZ-free or TZ- 
loaded micelles was effective in decreasing the population 
of cancer stem cells. However, TZ-loaded micelles had lower 
antitumor efficacy than doxorubicin-loaded micelles; the 
combination therapy of TZ-loaded and doxorubicin-loaded 
micelles presented a greater antitumor effect than 
doxorubicin-loaded micelles alone (42).
The first demonstrations that phenothiazines could inhibit 
cancer growth were reported during the early 1950s. Since
Role of TZ in Combined Chemotherapy
Conclusion
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those early years, many studies have been published 
describing that phenothiazines can inhibit the growth of 
some types of cancers (43). Based on the biological activity 
of TZ, such as interference with membrane function, DNA 
repair, signaling pathways, cell cycle, apoptosis induction, 
efflux inhibition and, also, its synergistic ^ffect with 
doxorubicin, renders TZ a powerful anticancer drug and 
adjuvant in combined chemotherapy.
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